# (TNX-1500) in Kidney Transplant Recipients

> **NCT07204080** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ayman Al Jurdi, MD** · enrollment: 5 (estimated)

## Conditions studied

- Kidney Transplant
- Kidney Transplant Failure and Rejection
- Immunosuppression
- Immunosuppression After Kidney Transplantation

## Interventions

- **DRUG:** TNX-1500
- **PROCEDURE:** Kidney Transplant

## Key facts

- **NCT ID:** NCT07204080
- **Lead sponsor:** Ayman Al Jurdi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-06-30
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- Tonix Pharmaceuticals, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204080, "(TNX-1500) in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07204080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*